Chemoprevention of breast cancer

JAMA

Volumn 275, Issue 17, 1996, Pages 1349-1353

  O'Shaughnessy, Joyce A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; DROLOXIFENE; FENRETINIDE; GENISTEIN; OLTIPRAZ; PRASTERONE; RETINOID; RETINOL; TAMOXIFEN; TOREMIFENE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER HORMONE THERAPY; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER;

EID: 0029989983     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.17.1349     Document Type: Article

References (50)

1. Vogel VG. Subjects and recruitment strategies for a short-term phase II chemoprevention trial of breast cancer using surrogate endpoint biomarkers. J Cell Biochem. 1993;17G(suppl):257-258.
2. Vogel VG. High-risk populations as targets for breast cancer prevention trials. Prev Med. 1991; 20:86-100.
3. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.
4. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol. 1985;16:796-807.
5. Boone CW, Kelloff GJ. Intraepithelial neoplasia surrogate endpoint biomarkers and cancer chemoprevention. J Cell Biochem. 1993;17F(suppl) :37-48.
6. Kelloff GJ, Boone CW, Steele VE, et al. Development of breast cancer chemopreventive drugs. J Cell Biochem. 1993;17G(suppl):2-13.
7. Russo IH, Russo J. Physiological bases of breast cancer prevention. Eur J Cancer Prev. 1993;2(suppl 3):101-111.
8. Russo J, Russo IH. Is differentiation the answer in breast cancer prevention? IRCS Med Sci. 1982; 10:935-941.
9. Russo IH, Russo J. Developmental stage of the rat mammary gland as determinant of its susceptibility to 7,12-dimethylbenz(s)anthracene. J Natl Cancer Inst. 1978;61:1439-1449.
10. Russo J, Russo IH. Mammary tumorigenesis. Prog Exp Tumor Res. 1991;33:175-191.
11. Pike MC, Spicer DV. The chemoprevention of breast cancer by reducing sex steroid exposure. J Cell Biochem.1993;17G(suppl):26-36.
12. Khan SA, Rogers MAM, Obando JA, et al. Estrogen receptor expression of benign breast epithelia and its association with breast cancer. Cancer Res. 1994;54:993-997.
13. Osborne MP, Bradlow HL, Wong GYC, et al. Upregulation of estradiol c16α-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst. 1993;85:1917-1920.
14. Swisshelm K, Ryan K, Lee X, et al. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its upregulation in senescing normal mammary epithelial cells. Cell Growth Differ. 1994;5:133-141.
15. Glick AB, McCure BK, Abdulkareum N, et al. Complex regulation of TGF beta expression by retinoic acid in the vitamin A deficient rat. Development 1991;111:1081-1086.
16. Younes M, Fernandez R, Laucinca R. Transforming growth factor β receptor II (TGFβ-RII) is infrequently expressed in breast cancer. Proc Am Assoc Cancer Res. 1995;36:3726a.
17. Pavelic ZP, Pavelic L, Lauer EL, et al. c-myc, c-erbB-2, and Ki67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res. 1992;53:2597-2602.
18. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinoma from non-malignant lesions. Nat Med. 1995;1:1257-1260.
19. Eriksson ET, Schimmelpenning H, Aspenblad U, et al. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum Pathol. 1994;25:1228-1233.
20. Yee D, Paik S, Lebovic GS, et al. Analysis of IGF-1 gene expression in malignancy. Mol Endocrinol. 1989;3:509-517.
21. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-484.
22. Breast Cancer Trials Committee, Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987;2:171-175.
23. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989;1:117-120.
24. Abram WP, Baum M. Berstock DA, et al. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer. 1988;57:604-607.
25. McDonald CC, Stewart HJ, for the Scottish Breast Cancer Committee. Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial. BMJ. 1991;303:435-437.
26. Love RE, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852-856.
27. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78-84.
28. Van Leeuven, Febenraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
29. Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. In: Proceedings of Chemopreventive Agents: Drug Development Status and Future Prospects, October 18-22, 1994, Princeton, NJ. Bethesda, Md: National Cancer Institute; 1994:28.
30. Draper MW, Flowers DE, Huster WJ, et al. Effects of raloxifene (LY 139481 HCI) on biochemical markers of bone and lipid metabolism in healthy premenopausal women. In: Proceedings of the Fourth International Symposium on Osteoporosis. In press.
31. Anzano MA, Byers SW, Smith JM, et al. Prevention of breast cancer in the rat with 9-cis retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 1994;54:4610-4614.
32. Ratko TA, Detrisac CJ, Dinger NM. et al. Chemopreventive efficacy of combined retinoid and tamoxifes treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 1989;49:4472-1476.
33. Torrisi R, Pensa F, Orengo MA, et al. The synthetic retinoid fenretinide lowers plasma insulinlike growth factor I levels in breast cancer patients. Cancer Res. 1993;53:4769-4771.
34. Bacus SS, Kiguchi K, Chin D, et al. Differentiation of cultures of human breast cancer cells (AU-585 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol Carcinog. 1990;3:350-362.
35. McCormick DL, Johnson WD, Rao KVN, et al. Chemoprevention of rat mammary carcinogenesis: exceptional activity of dietary dehydroepiandrosterone (DHEA). J Cell Biochem 1993;17G(suppl): 253-254.
36. Jirtle RL, Haag JD, Ariazi EA, et al. Increased mannose 6-phosphate/insalin-like growth factor II receptor and transforming growth factor β1 levels during monoterpene-induced regression of mammary tumors. Cancer Res. 1993;53:3849-3852.
37. Messina MJ, Pensky V, Setchell KD. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994;21:113-131.
38. Rose DP, Boyer AP, Wynder EL. International comparisons of mortality rates for cancers of the breast, ovary, prostate, and colon and per capita food consumption. Cancer. 1986;58:2363-2371.
39. Fabian CJ, Zalles C, Kamel S, et al. Biomarker and cytologic abnormalities in women at high risk and low risk for breast cancer. J Cell Biochem. 1993;17G(suppl):153-160.
40. Dupont W, Page D. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol. 1989;20:723-725.
41. Frykberg E, Santiago F, Betsill W, et al. Lobular carcinoma in situ of the breast. Surg Gynecol Obstet. 1987;164:285-301.
42. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Cancer. 1994;73:643-651.
43. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor β in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med. 1995;332:1405-1410.
44. Christov K, Chew KL, Ljung BM, et al. Cell proliferation in hyperplastic and in situ carcinoma lesions of the breast estimated by in vivo labelling with bromodeoxyuridine. J Cell Biochem. 1994;19 (suppl):165-172.
45. McKittrick R, Fabian C, Kamel S, et al. Dysplasia and other biomarker abnormalities as potential surrogate endpoint biomarkers in breast chemoprevention trials. Proc Am Soc Clin Oncol. 1995; 14:A348. Abstract.
46. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1885.
47. Buring JE. β-Carotene and cancer chemoprevention: the epidemiologic evidence. In: Proceedings of Chemopreventive Agents: Drug Development Status and Future Prospects, October 18-22, 1994, Princeton, NJ. Bethesda, Md: National Cancer Institute; 1994.
48. DePalo G, Veronesi U, Camerini T, et al. Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst. 1995;87:146-147.
49. Butta A, MaeLennon K, Flanders KC, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992;52:4261-4264.
50. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:513-918.